Chemotherapeutic solutions containing a sulphur and a salt of a 2,4-diamino-5-benzylpyrimidine

Claim 2

A clear solution which includes 1 to 40 per cent (w/v) of sulfamethoxazole, 1 to 10 percent (w/v) of trimethoprim calculated as base in the form of a water soluble pharmaceutically acceptable acid addition mono salt, 10 to 60 percent water (v/v) and 30 to 90 percent (v/v) of a water miscible organic solvent for the sulfamethoxazole, the solution having a pH of 4.0 to 7.0, and a solution in which the organic solvent is selected from the class consisting of N, N-dimethylacetamide, polyethylene glycols having average molecular weights from about 190 to 7500 and containing 2 to 159 ethylene glycol monomer units, 1, 2-propylene glycol, glycerin, hexamethylene glycol, 1,3-butylene glycol, ethanol, diethylacetamide, dimethylsulfoxide, dimethylformamide, di 1,2-propylene glycol, glycerin formal, polyethylene-glycoethers of tetrahydrofurfuryl alcohol and diethylene glycol.

Claim 3

A solution according to claim 1 in which the salt is the lactate salt.

Claim 4

A solution according to claim 1 wherein the ratio of sulfamethoxazole to trimethoprim as base is 20:1 to 0.1:1.

Claim 5

A solution according to claim 3 in which the solution contains from 0.5 to 3.5 percent of a pharmaceutically acceptable acid.

Claim 6

The solution of claim 1 which has a pH between 4 to 6.

Claim 7

The solution of claim 1 which has a pH of 4.5 to 5.5.

Claim 8

A clear solution for oral or parenteral use including (a) 1 to 40 per cent (w/v) of a sulphonamide selected from the group consisting of sulfadimethoxine, sulphadiazine, sulfadoxine, sulphadimethoxine, sulphamethoxazol, sulphaquinoxaline, sulphadimidine, sulfafurazole and sulfacetamide; (b) 30 to 90 percent (v/v) of a medicinally acceptable water miscible organic solvent for the sulphonamide, said organic solvent is selected from the class consisting of N,N-dimethylacetamide, polyethylene glycols having average molecular weights from about 190 to 7500 and containing 2 to 159 ethylene glycol monomer units, 1,2-propylene glycol, glycerin, hexamethylene glycol, 1,3-butylene glycol, ethanol, diethylacetamide, dimethylsulfoxide, dimethylformamide, di 1,2-propylene glycol, glycerin formal, polyethylene-glycoethers of tetrahydrofurfuryl alcohol and diethylene glycol; (c) 1 to 10 percent (w/v) of sulphonamide potentiator calculated as a base, in the form of a water soluble, pharmaceutically acceptable mono acid addition salt, said sulphonamide potentiator being of formula I ##SPC4## wherein R 1 is hydrogen or lower alkyl, wherein R 3 and R 4 are hydrogen, halogen, lower alkyl, lower alkoxy and wherein one or both R 5 and R 6 are halogen, lower alkyl and lower alkoxy; and (d) 10 to 60 percent water (v/v) said solution having a pH in the range of 2 to 7.

Claim 9

A clear solution for oral or parenteral use including (a) 1 to 40 per cent (w/v) of a sulphonamide selected from the group consisting of sulfadimethoxine, sulphadiazine, sulfadoxine, sulphadimethoxine, sulphamethoxazol, sulphaquinoxaline, sulphadimidine, sulfafurazole and sulfacetamide; (b) 30 to 90 percent (v/v) of a medicinally acceptable water miscible organic solvent for the sulphonamide, said organic solvent is selected from the class consisting of N,N-dimethylacetamide, polyethylene glycols having average molecular weights from about 190 to 7500 and containing 2 to 159 ethylene glycol monomer units, 1,2-propylene glycol, glycerin, hexamethylene glycol, 1,3-butylene glycol, ethanol, diethylacetamide, dimethylsulfoxide, dimethylformamide, di 1,2-propylene glycol, glycerin formal, polyethylene-glycoethers of tetrahydrofurfuryl alcohol and diethylene glycol; (c) 1 to 10 percent (w/v) of sulphonamide potentiator calculated as a base, in the form of a water soluble, pharmaceutically acceptable mono acid addition salt, said sulphonamide potentiator being of formula I ##SPC4## wherein R 1 is hydrogen or lower alkyl, wherein R 3 and R 4 are hydrogen, halogen, lower alkyl, lower alkoxy and wherein one or both R 5 and R 6 are halogen, lower alkyl and lower alkoxy; and (d) 10 to 60 percent water (v/v) said solution having a pH in the range of 2 to 7.

Claim 10

A solution as claimed in claim 7 wherein R 3 is hydrogen, and R 4 , R 5 and R 6 are the same or different and represent an alkyl or alkoxy group having from 1 to 4 carbon atoms.

Claim 11

A solution according to claim 7 in which the sulphonamide potentiator is represented by the formula: ##STR2## where R 1 , R 2 and R 3 are the same or different and can each represent alkyl or alkoxy groups having from 1 to 4 carbon atoms.

Claim 12

A solution according to claim 9 in which R 1 , R 2 , and R 3 are methoxy.

Claim 13

A solution according to claim 9 wherein the sulphonamide is sulfamethoxazole.

Claim 14

A solution according to claim 7 in which the sulphonamide is present in an effective antibacterial or antiprotozoal treatment amount and in which the sulphonamide potentiator is present in an effective sulphonamide potentiating amount.

Claim 15

A method of treating an animal or mammal suffering from bacterial or protazoal infections which comprises administering to said animal or mammal a therapeutically effective antibacterial or antiprotozoal treatment amount of the solution of claim 7.

Claim 16

A method according to claim 13 in which the sulphonamide is sulfamethoxazole and the potentiator is trimethoprim.